AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01094756 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: meal replacements, psychotherapy, dietary education
Description: After the screening and scan days are completed, obese subjects will begin a lifestyle intervention program that includes dietary (low-calorie diet) and behavioral education topics. Treatment will be provided in individual weekly sessions. Each hour-long session will be led by a behavioral counselor or registered dietitian in the Weight Management Center at Washington University. The behavioral program will use cognitive-behavioral techniques to foster adherence to diet prescriptions and to build a supportive environment for the participant. The program will emphasize strategies of self-monitoring and goal-setting, and will include problem-solving, overcoming high-risk situations for unhealthy eating, relapse prevention, and strategies for long-term weight maintenance. Handouts will be provided for study subjects to allow them to record the setting and reaching of dietary goals, as well as summarize the key points of the educational content.
Study NCT02321631 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EPA-enriched supplement
Description: EPA-enriched supplement is given to the patients for 3 weeks (1 week prior to surgery and 2 weeks post surgery). The supplement composes of 2.2 gm of EPA and 630 kcal daily.
Study NCT02321631 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: standard formula supplement
Description: The standard formula supplement is given to the patients for 3 weeks (1 week prior to surgery and 2 weeks post surgery). The supplement is 630 kcal daily without EPA.
Study NCT02288351 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Mix Nutrient Meal
Description: Before Surgery: Subjects will have a visit where they will have a mixed nutrient stimulation test. They will be asked to fast for 12 hours prior to this visit (except water). During the visit they will drink an 8 ounce mixed nutrient liquid meal in 5 minute intervals over 20 minutes. During this visit a catheter will be placed in a vein in their arm for blood sample collections. A total of 50 ml of blood will be collected, (10 ml before drinking the mixed nutrient drink, at 30 minutes, at 60 minutes, at 90 minutes and 120 minutes after the mixed nutrient drink).
Study NCT01021579 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin plus Placebo
Description: PCOS patients(n=42) will be assigned to the placebo (once/day) plus metformin (500mg three times a day, n=42; group 2)
Study NCT01021579 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metfomin plus Simvastatin
Study NCT04669327 — intervention group
Intervention type: OTHER
Intervention: gait analysis
Description: Vicon nexus with MTI force plate form
Study NCT04215250 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: andropulous method
Description: Counts the CVC depth using specific equation
Study NCT04215250 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ECG
Description: Using ECG to monitor the insertion of the CVC
Study NCT01369160 — intervention group
Intervention type: BEHAVIORAL
Intervention: Quality of Life measures
Description: measuring QOL with different therapies
Study NCT01469624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: pentoxifylline 400 mg PO three times a day for 24 hours before and 24 hours after PCI
Study NCT01222884 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Monofer
Description: Iron isomaltoside 1000 (Monofer®) administered as 500 mg intravenous single bolus injection over approximately 2 minutes
Study NCT04465890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC22
Description: 200mg/1ml/1bottle
Study NCT04465890 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sodium chloride
Description: 90mg/10ml/1 bottle
Study NCT03904719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM082 plus JS001
Description: CM082: 150mg once a day orally (taken within half an hour after breakfast) JS001: An intravenous infusion of a solution having a concentration of 1-3mg/ml was prepared with 0.9% physiological saline, and administered once every three weeks. Using an inline filter (0.2 or 0.22 μm), the drug was diluted with physiological saline and intravenously administered within 60 minutes.
Study NCT01222884 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron sucrose
Description: Iron sucrose is administered undiluted in doses of 100mg at baseline, 200mg at week 2 and 200 mg at week 4 as fractionated IV bolus injections according to local Summary of Product Characteristics
Study NCT01841177 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Milrinone
Description: Milrinone is a potent selective phosphodiesterase (PDE) type III inhibitor which stimulates myocardial function (inotropy), causes peripheral vasodilatation (afterload reduction) and improves myocardial relaxation (lusitropy).
Study NCT03510715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin
Description: Pharmaceutical form: tablet,~Route of administration: oral
Study NCT03510715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovastatin
Description: Pharmaceutical form: tablet,~Route of administration: oral
Study NCT03510715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Pharmaceutical form: tablet,~Route of administration: oral
Study NCT04406779 — intervention group
Intervention type: DEVICE
Intervention: thyroid USG was perform, blood samples were taken for the meausurement of thyroid hormone and autoantibodies
Description: thyroid USG was perform, blood samples were taken for the meausurement of thyroid hormone and autoantibodies
Study NCT02029053 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Vaginal Lubrication Ring for Vaginal Dryness
Description: Participants will be asked to complete 4 study visits and one final follow-up phone call. Each study visit will include a brief vaginal exam where vaginal fluid levels and pH levels are checked and questionnaires are completed. Daily diaries will be completed at home and returned to the study staff at subsequent visits.~Participants will self-insert the Intravaginal ring on the 1st study visit. The 2nd study visit will occur 3-4 days later.~The 3rd study visit will occur approximately 7 days after the 1st visit. Participants will remove the device and self-insert a new intravaginal ring.~The 4th study visit will occur approximately 14 days after the first visit. Participants will remove the intravaginal ring and undergo a final vaginal exam.~Participants will be called approximately 7 days after the last visit and will be asked about their current vaginal dryness symptoms and how they felt about the device during the study.
Study NCT00867347 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic conventional surgery
Description: Patients undergo radical cystectomy
Study NCT00867347 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Patients undergo radiotherapy
Study NCT01841177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milrinone
Description: Milrinone is a potent selective phosphodiesterase (PDE) type III inhibitor which stimulates myocardial function (inotropy), causes peripheral vasodilatation (afterload reduction) and improves myocardial relaxation (lusitropy).
Study NCT04139473 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hepaticojejunostomy / Duct-to-duct anastomosis
Study NCT03995836 — intervention group
Intervention type: DEVICE
Intervention: CPAP
Description: Decision of CPAP treatment is according to clinical guidelines
Study NCT03995836 — intervention group
Intervention type: PROCEDURE
Intervention: Bariatric Surgery
Description: All patients.
Study NCT00703196 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: folic acid
Description: Given orally once daily
Study NCT00703196 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally once daily
Study NCT02969551 — intervention group
Intervention type: DEVICE
Intervention: Manometry and possibly DISE
Description: A Manometry is performed on all patients. After it in some Patient DISE is followed
Study NCT01090973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBH589
Description: The LBH589 capsule(s) should be swallowed by mouth with a glass of water (8 ounces noncarbonated) in the morning. The daily dose of LBH589 should be taken at approximately the same time each day. Patients should avoid eating grapefruit, Seville (sour) orange or drinking grapefruit juice or Seville orange juice during the study.~After 2 cycles of treatment, if patients do not demonstrate a partial response or complete response (all of the tumor is gone) to the therapy they will be removed from the study. If patients do obtain a partial (the tumor(s) have decreased in size or number but there are still tumors present) or complete response then treatment will continue until their disease progresses.
Study NCT04515446 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Rapid test for diagnosis orientation
Description: Rapid tests screen for influenza viruses in less than 30 minutes. They detect internal viral nucleoproteins by immunochromatography using specific antibodies attached to one or more strips.
Study NCT03510715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: Pharmaceutical form: tablet,~Route of administration: oral
Study NCT03510715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholestyramine
Description: Pharmaceutical form: oral suspension,~Route of administration: oral
Study NCT03510715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotinic acid
Description: Pharmaceutical form: tablet,~Route of administration: oral
Study NCT04515446 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: quantitative PCR
Description: Molecular biology method of gene amplification in vitro. It allows a large number of known DNA or RNA sequences to be duplicated
Study NCT01848704 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: interpretation of the abstract
Study NCT01848704 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: interpretation of the abstract
Study NCT01336192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1250mg/m\^2 Day 1 and 8, 28 days per cycle until PD
Study NCT01336192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Best supportive care
Description: Best supportive care
Study NCT03510715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Description: Pharmaceutical form: tablet,~Route of administration: oral
Study NCT03510715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Description: Pharmaceutical form: capsule,~Route of administration: oral
Study NCT05007158 — intervention group
Intervention type: OTHER
Intervention: procalcitonin blood test
Description: blood samples of all participants were analyzed for procalitonin levels, using a commercially available procalitonin testing kit
Study NCT03366012 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Cytosponge
Description: The Cytosponge consists of a 3cm diameter, polyester, medical grade spherical sponge on a string, compressed within a gelatin capsule. The capsule is swallowed while the patient or the research specialist holds onto the string. After 3-5 minutes the gelatin capsule dissolves allowing the spherical sponge to expand. The sponge is then retrieved by gently pulling on the string, thus collecting cells along the passageway through the entire length of the esophagus. The sample is then put into a preservative to be processed for immunohistochemical testing for trefoil factor 3 (TFF3) to determine diagnosis of Barrett's esophagus.
Study NCT03989414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-92480
Description: Specified dose on specified days
Study NCT03989414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Specified dose on specified days
Study NCT03989414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Specified dose on specified days
Study NCT03720808 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balloon Blowing
Description: The parents of the children in this group were asked whether their children had the latex allergy or not and the children without the allergy were included in the group. The children's skills of blowing balloon were observed before the procedure. Before starting the venous blood sampling procedure, the children were asked to choose a balloon in the color they preferred and to start blowing the balloon at least 20 seconds before the procedure. Venous blood sampling started as the children exhaled to blow up the balloon. Until the venous blood procedure ended, they continued to blow up the balloons.
Study NCT03720808 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ball Squeezing
Description: Before the venous blood collecting procedure, a soft ball was given to the right hands of the children and they were asked to squeeze and release this ball during the procedure.
Study NCT03720808 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coughing
Description: The children included in this group were asked to cough after taking a deep breath during the venous blood sampling procedure. Before the procedure, the researcher showed the children how they should cough and asked them to imitate. The venous blood sampling was not performed until the child successfully completed coughing. The child was directed by the researcher during the procedure. Just before the entrance of the needle, the child was asked to take a deep breath and the venous blood sampling procedure was started during coughing.
Study NCT03720808 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: No intervention was performed to reduce pain and fear in the control group.
Study NCT04670484 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Wearing Mask
Description: Participants wearing masks as per federal guidelines to prevent Coronavirus spread
Study NCT03449576 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trauma Management Therapy
Description: Trauma Management Therapy (TMT) consists of a combination of 12 sessions of individualized exposure therapy and 24 sessions of group-based social and emotion rehabilitation.
Study NCT03449576 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exposure Therapy with Psychotherapy group
Description: Exposure Therapy with Psychoeducation (EXP+EDU) consists of a combination of 12 sessions of individualized exposure therapy and 24 session of group-based psychoeducation.
Study NCT03633201 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cruciate Retaining
Description: Zimmer Biomet's Personalized Knee system for knee osteoarthritis treatment. The standard insert.
Study NCT03633201 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medial Congruent
Description: Zimmer Biomet's Personalized Knee system for knee osteoarthritis treatment. The new anatomical congruent shaped insert.
Study NCT04206787 — intervention group
Intervention type: DRUG
Intervention: Afatinib
Description: drug
Study NCT03077061 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open flap debridement
Description: Open flap debridement using saline as irrigation
Study NCT03077061 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open flap debridement
Description: Open flap debridement using saline as irrigation
Study NCT03077061 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bone replacement graft
Description: Open flap debridement using saline as irrigation including a grafting procedure withBio-Oss Collagen®.
Study NCT03830398 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: The investigators apply paracetamol during a week in preoperative room 45 min before ECT
Study NCT03830398 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Deksketoprofen trometamol
Description: The investigators apply paracetamol during a week in preoperative room 45 min before ECT
Study NCT03830398 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The investigators apply placebo during a week in preoperative room 45 min before ECT
Study NCT04799535 — intervention group
Intervention type: PROCEDURE
Intervention: Ultrasound
Description: Undergo breast ultrasound
Study NCT00716079 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood pressure management policies
Description: The trial is an assessment of BP lowering management strategies, using routinely available drugs. There is some flexibility in the use of particular BP lowering agents to achieve BP targets.
Study NCT00703482 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fenofibrate/CoQ10
Description: Fenofibrate pbo/CoQ10 placebo
Study NCT00703482 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fenofibrate/CoQ10
Description: Fenofibrate pbo/CoQ10 200 mg
Study NCT00703482 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fenofibrate/CoQ10
Description: Fenofibrate 160mg/CoQ10 placebo
Study NCT00703482 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fenofibrate/CoQ10
Description: Fenofibrate 160mg/CoQ10 placebo
Study NCT00703482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate/CoQ10
Description: Fenofibrate 80/CoQ10 100 mg
Study NCT00703482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate/CoQ10
Description: Fenofibrate 160mg/CoQ10 100 mg
Study NCT00703482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate/CoQ10
Description: Fenofibrate 80 /CoQ10 200 mg
Study NCT02288351 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: labs
Description: Fasting Plasma Glucose (FPG) and insulin will be added to the standard pre-operative labs.
Study NCT02288351 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Biopsy
Description: Intra-operatively: Subjects will undergo a standard laparoscopic Roux-en-Y Gastric Bypass (RYGB). During the surgery a 2cm tissue sample of the Roux limb will be taken by the doctor and frozen.
Study NCT00703482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate/CoQ10
Description: Fenofibrate 160mg/CoQ10 200 mg
Study NCT03097211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsules. Orally, with 240 mL of potable water.
Study NCT02637791 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual glove
Description: The intervention (the virtual glove) consists of a hand-mounted power unit, with four infra- red light emitting diodes (LEDs) mounted on the user's finger tips. The LEDs are tracked using one or two Nintendo Wii motes mounted by the computer screen on which the games are displayed to translate the location of the user's hand, fingers and thumb in 3D space. Three games have been produced especially for the project with the help of therapists and stroke patients. In order to play them, users have to perform the movements of reach to grasp, grasp and release, pronation and supination that are necessary to effect many activities of daily living.
Study NCT05344079 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 18-Gauge Touhy (Egemen®, Combifix Standard Spinal Epidural Combined Set, İzmir, Turkey)
Description: Patients in this group were entered the epidural space from the midline using the loss of resistance method with an 18-Gauge Touhy (Egemen®, Combifix Standard Spinal Epidural Combined Set, İzmir, Turkey) needle from the L4-L5 or L5-S1 vertebral space. After the free cerebrospinal fluid flow is observed by passing the spinal needle through the epidural needle, spinal anaesthesia was maintained with 10-15 mg hyperbaric bupivacaine (Bustesin®, 0.5% Spinal Heavy Vem Pharmaceuticals, Turkey). After the epidural catheter was fixed in such a way that it remained 5 cm in the epidural space, the adapter was inserted and fixed. Whether the catheter is in place or not was checked by 2 mL (40 mg) Lidocaine (Aritmal®, 2% 100 mg/5 mL amp., Biosel, Turkey) + 1/2000000 adrenaline test dose.
Study NCT03097211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 6-512
Description: The investigational products consisted of capsules containing BIA 6-512 25 mg, 50 mg, 75 mg, 100 mg. Orally, with 240 mL of potable water.
Study NCT03097211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Madopar® 250
Description: Levodopa/benserazide immediate release tablets 200mg/50mg. Orally, with 240 mL of potable water.
Study NCT02288351 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Second Mix Nutrient Meal
Description: 2 months post-operatively a second mixed nutrient stimulation test will be performed following the same process used pre-operatively.
Study NCT02288351 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Second biopsy
Description: . Patients will also be scheduled to undergo a second upper endoscopy and a 2cm biopsy of the Roux limb will be taken by the doctor and frozen in liquid nitrogen.
Study NCT03097211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebicapone
Description: Nebicapone 150 mg tablets. Orally, with 240 mL of potable water.
Study NCT02288351 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: PET/CT
Description: Lastly, subjects will have a positron emission tomography/computed tomography (PET/CT) scan with Fluorodeoxyglucose (FDG) to evaluate the glucose in the Roux limb after surgery.
Study NCT03037424 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octafibrin
Description: Octafibrin will be administered when the blood bank receives an order for fibrinogen supplementation